Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease Source: Eur Respir J, 49 (6) 1601923; 10.1183/13993003.01923-2016 Year: 2017
Relationship between OSA and non-alcoholic fatty liver disease Source: ERS Conference Year: 2015
In sleep apnea patients nonalcoholic fatty liver disease (NAFLD) is associated with the severity of intermittent hypoxia and more severe endothelial dysfunction Source: Annual Congress 2012 - Sleep disorders in internal medicine Year: 2012
The influence of obstructive sleep apneao–induced intermittant Hypoxia on Non Alcoholic Fatty liver. Source: International Congress 2017 – Pathophysiological aspects of comorbid conditions in obstructive sleep apnoea Year: 2017
Increased risk of obstructive sleep apnoea in patients with non-alcoholic fatty liver disease Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012
Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? Source: Eur Respir J, 49 (6) 1700546; 10.1183/13993003.00546-2017 Year: 2017
Association between obstructive sleep apnea and the severity of non-alcoholic fatty liver disease. Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019
The impact of severe obstructive sleep apnea and obesity on nonalcoholic fatty liver disease. Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities Year: 2017
Association between obstructive sleep apnea and nonalcoholic fatty liver disease Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases Year: 2019
Non-alcoholic fatty liver disease (NAFLD): A new mechanism for co-morbidities in chronic obstructive pulmonary disease (COPD)? Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016
Impact of non-alcoholic fatty liver disease on late cardiovascular events and death in Chronic Obstructive Pulmonary Disease Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018
Effects of n-3 polyunsaturated fatty acids on inflammatory markers in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 39s Year: 2006
Fat metabolism in chronic respiratory disease Source: ISSN=1025-448x, ISBN=1-904097-27-8, page=34 Year: 2003
Chronic intermittent hypoxia induces features of non alcoholic fatty liver disease (NAFLD) and modifies adipose tissue characteristics in lean mice Source: International Congress 2014 – Inflammation and obesity: implications for OSA Year: 2014
Is heart type fatty acid binding protein a marker of cardiac damage in patients with acute attacks of chronic obstructive pulmonary disease? Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008
1-year outcomes for lung transplantation recipients with non-alcoholic fatty liver disease Source: ERJ Open Res, 7 (3) 00103-2021; 10.1183/23120541.00103-2021 Year: 2021
Oxidant metabolism in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 14S-27S Year: 2003
Protein metabolism in chronic respiratory disease Source: ISSN=1025-448x, ISBN=1-904097-27-8, page=23 Year: 2003
Regulation disorders of pulmonary lipid metabolism in chronic obstructive pulmonary disease Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019
Uric acid, oxidative stress and inhaled steroids in stable chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006